S.Korea's Hanmi Pharm soars, diabetes drug enters phase 2 clinical trial
** Shares of Hanmi Pharm Co Ltd 128940.KS jump nearly 9
pct to a two-month high
** Hanmi Pharm's drug for diabetes entered into phase 2
clinical trial with two more trials scheduled for H1 of this
year, an analyst with SK Securities said in a note
** Hanmi Science 008930.KS , Hanmi Pharm's holding company,
also up 5.4 pct
** Broader market .KS11 up 0.3 pct as of 0248 GMT
((Reuters Messaging: dahee.kim@thomsonreuters.com))
Recent news on Hanmi Pharm
See all newsBrief: Hanmi Pharm To Cancel 28 Billion Won Worth Of Own Shares
Brief: Hanmi Pharm Q3 Operating Profit 37.8 Billion Won, Down 31.3% From Year Earlier
Brief: Hanmi Pharm Co Signs License Out Agreement With Genetech Inc. In U.S.
Brief: Hanmi Pharm Co Enters License Agreement With Eli Lilly For Sonefpeglutide
Brief: Hanmi Pharm Co Ltd Wins 53 Billion Won Order